RT Book, Section
A1 Tolaney, Sara M.
A1 Krop, Ian E.
A2 Kuerer, Henry M.
SR Print(0)
ID 6417137
T1 Chapter 87. Adjuvant Chemotherapy
T2 Kuerer's Breast Surgical Oncology
YR 2010
FD 2010
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-160178-8
LK accesssurgery.mhmedical.com/content.aspx?aid=6417137
RD 2024/04/25
AB The  goal  of  adjuvant  systemic  therapy  for  early-stage  breast  cancer  is  to  eliminate  micrometastatic  disease,  thus  preventing  future  recurrences.  Adjuvant  systemic  therapy,  chemotherapy,  targeted  therapy,  and/or  endocrine  therapy,  has  led  to  a  substantial  decline  in  breast  cancer  mortality  in  women  with  operable  breast  cancer.  Although  chemotherapy  can  be  effective  in  preventing  distant  failure,  not  all  patients  benefit.  Many  patients  would  remain  disease  free  without  therapy,  and  others  would  relapse  despite  treatment.  The  decision  to  use  adjuvant  chemotherapy  involves  a  careful  assessment  of  its  benefits  and  potential  risks.  New  insights  into  the  biology  of  breast  cancer  have  provided  improved  tools  to  predict  more  accurately  the  benefits  of  chemotherapy  in  a  given  patient,  thus  allowing  chemotherapy  to  be  used  in  patients  who  most  likely  will  benefit  and  sparing  those  who  are  less  likely  to  benefit.  This  chapter  focuses  on  adjuvant  systemic  chemotherapy;  the  benefit  of  targeted  therapy  and  endocrine  therapy  are  detailed  elsewhere  in  this  text.